Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Oct 2021

Sztupinszki Zsofia, Diossy Miklos, Borcsok Judit, Prosz Aurel, Cornelius Nanna, Kjeldsen Maj K, Mirza Mansoor R, Szallasi Zoltan

Abstract excerpt

PURPOSE: Homologous recombination (HR) deficiency (HRD) is one of the key determinants of PARP inhibitor response in ovarian cancer, and its accurate detection in tumor biopsies is expected to improve the efficacy of this therapy. Because HRD induces a wide array of genomic aberrations, mutational signatures may serve as a companion diagnostic to identify PARP inhibitor-responsive cases. EXPERIMENTAL DESIGN: From...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to DNA Repair Mechanisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Homologous Recombination

Share to Mutation

Share to Ovarian Neoplasms

Share to PARP inhibition in cancer therapy

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Identifiers

PMID: 34380641
DOI: 10.1158/1078-0432.CCR-21-0981

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer.PMID 34380641Read ↗

Detecting HRD in whole-genome and whole-exome sequenced breast and ovarian cancersSemantic proximity Read ↗

HRProfiler Detects Homologous Recombination Deficiency in Breast and Ovarian Cancers Using Whole-Genome and Whole-Exome Sequencing Data.Semantic proximity Read ↗

Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancerSemantic proximity Read ↗

Unraveling Homologous Recombination Deficiency in Ovarian Cancer: A Review of Currently Available Testing PlatformsSemantic proximity Read ↗

HRDex: a tool for deriving homologous recombination deficiency (HRD) scores from whole exome sequencing dataSemantic proximity Read ↗

The utility of homologous recombination deficiency biomarkers across cancer typesSemantic proximity Read ↗

Utility of Homologous Recombination Deficiency Biomarkers Across Cancer TypesSemantic proximity Read ↗

Whole-exome sequencing provides assessment of homologous recombination deficiency for identification of PARPi-responsive ovarian tumors.Semantic proximity Read ↗

Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)Semantic proximity Read ↗

Benchmarking homologous recombination deficiency algorithms for prediction of clinical outcome in ovarian cancerSemantic proximity Read ↗

HRDetect in Ovarian Carcinoma: Stratification and Therapeutic ImplicationsSemantic proximity Read ↗

Whole Genome Landscape Analysis of Homologous Recombination Deficiency in a Pan-Cancer CohortSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.